Fiserv vs Moderna

Fiserv and Moderna are two companies operating in completely different industries but are both popular choices for investors looking to diversify their portfolios. Fiserv is a leading provider of technology solutions for the financial services industry, while Moderna is a biotechnology company focused on developing innovative vaccines and therapies. Both stocks have shown strong performance in recent years, with Fiserv benefiting from the shift towards digital payments and Moderna gaining recognition for its groundbreaking COVID-19 vaccine. Investors should carefully consider their risk tolerance and long-term investment goals before deciding to invest in either of these stocks.

Fiserv or Moderna?

When comparing Fiserv and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Fiserv and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Fiserv has a dividend yield of -%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Fiserv reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Fiserv P/E ratio at 32.76 and Moderna's P/E ratio at -3.75. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Fiserv P/B ratio is 4.02 while Moderna's P/B ratio is 1.88.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Fiserv has seen a 5-year revenue growth of 1.17%, while Moderna's is 10.71%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Fiserv's ROE at 11.86% and Moderna's ROE at -45.27%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $193.29 for Fiserv and $57.12 for Moderna. Over the past year, Fiserv's prices ranged from $109.12 to $195.83, with a yearly change of 79.46%. Moderna's prices fluctuated between $55.70 and $170.47, with a yearly change of 206.05%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.